The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Does a reduced dosing frequency of carfilzomib affect outcomes for patients with R/R myeloma?
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, discusses an analysis of real-world data that aimed to investigate carfilzomib prescribing patterns in relapsed/refractory (R/R) multiple myeloma (MM) and how these have changed over time. In the United States, once-weekly carfilzomib dosing has become the norm, with Dr Banerjee emphasizing that this does not impact the progression-free survival (PFS) of patients. A decrease in the dosing frequency of the agent comes with the benefit of decreased time toxicity, as patients do not have to visit the clinic several times per week. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Adaptive Biotechnologies, Bristol-Myers Squibb/Celgene, Caribou Biosciences, Genentech, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Legend Biotech, Pfizer, Sanofi, SparkCures; Research Funding: Abbvie, Bristol-Myers Squibb/Celgene, Janssen, Novartis, Pack Health/Quest Diagnostics, Prothena, Sanofi.
